Cervical Cancer Screening and Management

Initial Management

The National Comprehensive Cancer Network (NCCN) guidelines recommend colposcopy as the initial management for adult women with LGSIL and positive high-risk HPV results, excluding types 16 and 18, as seen in a 42-year-old patient 1
The American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines recommend colposcopy for women with LGSIL cytology, as HPV testing is not recommended for triage in these cases due to the high prevalence of HPV positivity 3
Colposcopy should be performed by adequately trained health professionals, as recommended by the Annals of Oncology 4
For women over 30 years of age, LSIL requires colposcopy regardless of HPV status, according to the NCCN guidelines 2

If colposcopy is satisfactory and results show CIN 1 or negative, follow-up with HPV DNA testing at 12 months or repeat cytology at 6 and 12 months is recommended, as per the American Journal of Obstetrics and Gynecology 5
If HPV DNA test is negative or two consecutive cytology tests are negative, return to routine screening, as recommended by the American Journal of Obstetrics and Gynecology 5
If HPV DNA test remains positive or cytology shows ASC-US or greater, repeat colposcopy, according to the American Journal of Obstetrics and Gynecology 5
If CIN 1 persists for at least 2 years, either continued follow-up or treatment is acceptable, as per the American Journal of Obstetrics and Gynecology 5

After negative follow-up results, the patient can return to routine screening with co-testing (cytology and HPV) every 5 years or cytology alone every 3 years, as recommended by the American Journal of Obstetrics and Gynecology, although this is also mentioned in Praxis Medical Insights, the AJOG reference is preferred 5

The absence of HPV types 16 and 18 is somewhat reassuring, as these types carry higher oncogenic potential than other high-risk HPV types, however, colposcopy is still warranted due to the LGSIL finding with positive high-risk HPV, as per Praxis Medical Insights, but the same information is available in other references 6
Avoid immediate excisional or ablative procedures for LGSIL/CIN 1 findings, as most of these lesions will regress spontaneously, according to the American Journal of Obstetrics and Gynecology 5
Ensure proper documentation and tracking of results to prevent loss to follow-up, which is a major risk factor for progression to invasive disease, as recommended by the MMWR Recommendations and Reports 7
The prior negative HPV test does not negate the need for colposcopy with the current positive findings, as per the NCCN guidelines 2